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Abstract
Background: Despite the uncertainty in the diagnosis of neuropsychiatric involvement in systemic lupus erythematosus
(SLE), attempts have been made to record the association of certain antibodies in serum with neuropsychiatric (NP)
manifestations. We aimed to assess the behaviour and the association of serum and cerebrospinal fluid (CSF) autoantibodies
with NP manifestations in SLE patients (NPSLE).
Methodology/Principal Findings: Forty-seven SLE patients, hospitalized because of NP manifestations were included. They
were evaluated at hospitalization and six months later, and serum and CSF samples were obtained at each evaluation. As
controls, serum samples were taken from 49 non-NPSLE patients at hospitalization and six months later; serum and CSF
samples were also obtained from 6 SLE patients with septic meningitis, 16 surgical SLE patients and 25 patients without
autoimmune diseases. Antinuclear, anti-dsDNA, anti-ribosomal P, Anti-N-Methyl-D-Aspartate receptor (NMDAR), anti-
cardiolipin, and anti-b2 glycoprotein-I antibodies were measured. In serum, anti-ribosomal P, anti-NMDAR, and other
antibodies did not differentiate among SLE groups, and the levels of all antibodies were similar among the SLE groups. Six-
months later, this scenario remained unchanged and the decrease in the levels of some autoantibodies reflected a decline in
disease activity, rather than a change in NPSLE. In CSF, only the presence and the levels of anti-NMDAR antibodies showed a
characteristic distribution in central NPSLE and septic meningitis patients. Six months later the prevalence of most
antibodies in CSF did not change, however the levels of anti-dsDNA, anti-ribosomal P, and anti-NMDAR decreased.
Conclusion: In NPSLE, autoantibodies in serum do not reflect their behaviour in CSF. All autoantibodies were elevated in
septic meningitis reflecting the global penetration of serum antibodies into the CSF in this condition. Anti-NMDAR
antibodies in CSF identified patients with central NPSLE; their continued presence in CSF 6 months after neurologic
symptoms raise questions regarding the conditions under which they are pathogenic.
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Introduction
Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by distinctive tissue pathology. Despite the presence
of autoantibodies and tissue damage, the relationship between
them remains controversial and clear explanations for many of the
clinical features are yet to be given [1].
Central nervous system (CNS) involvement is a commonly
encountered situation in which diagnostic certainty is lacking [2].
The clinical manifestations are diverse, ranging from mild affective
disorders to seizures, cognitive dysfunction and stroke. Other
conditions capable of causing neuropsychiatric disorders such as
severe hypertension and corticosteroid therapy frequently coexist
[3]. Furthermore, no laboratory or radiographic tests have been
reported that are both sensitive and specific in establishing the
diagnosis of NPSLE. In spite of this, attempts have been made to
record the association of certain antibodies, e.g., anti-ribosomal P,
anti-NMDAR, anti-phospholipids, with NPSLE, since the former
usually accompany the latter. Some reports have assessed the role
of these antibodies in the diagnostic evaluation of NPSLE [4–8]
and others have involved them in the pathogenesis of NP
manifestations [9–17]. Nonetheless, the question that remains
unanswered is whether these antibodies are a consequence of
NPSLE or they are one of its causes. A third option is that they are
merely an epiphenomenon.
The aim of the present study was to assess the association of
serum and CSF autoantibodies with NP manifestations in SLE
patients, and to provide insight into whether they participate in the
pathogenesis of NPSLE. According to the results observed, serum
autoantibodies may be misleading as a diagnostic tool in NPSLE,
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and central NPSLE in remission raise questions regarding the
circumstances in which they may be pathogenic.
Methods
Objective
To assess the behaviour and the association of serum and CSF
autoantibodies with NP manifestations in NPSLE patients.
Participants
Forty-seven SLE patients, [American College of Rheumatology
(ACR) criteria [18], hospitalized between February 2003 and June
2005, because of NP manifestations were included. All patients were
evaluated by the study rheumatologists and neurologists, at
hospitalization and six months later using a standardized protocol,
including disease activity assessment using the Systemic Lupus
Erythematosus Disease Activity Index 2000 (SLEDAI-2K) [19]. At
hospitalization, information on socio-demographic data, SLE
characteristics (i.e. age at diagnosis defined as the date of the fourth
lupus criteria, disease duration, SLE criteria accumulated, etc.), and
treatment was gathered, and the medical records were reviewed to
collect additional information, including chronic damage accrual
using the Systemic Lupus International Collaborating Clinics/ ACR
Damage Index [20]. A serum sample was obtained in all the patients
at hospitalization and in 39 patients six months later. A CSF sample
was obtained, in 40 patients at hospitalization and in 30 patients,
who consented a lumbar control punction, six months later.
Neuropsychiatric manifestations were classified using the ACR
nomenclature for neuropsychiatric lupus syndromes [21], and the
patients were categorized in a central NPSLE group: seizure
disorders 16, severe refractory headache 9, acute confusional state
8, cerebrovascular disease 7, psychosis 1, and pseudotumor cerebri
1; and a peripheral NPSLE group: multiplex mononeuritis 3,
transverse myelitis 1, and polyneuropathy 1. Neurpsychiatric
manifestations were attributed to SLE given that there were no
exclusion factors for it [21], and none of the patients had any of
the minor NP events which have been reported with a comparable
frequency in the general population [22]
As controls, 49 hospitalized SLE patients with no history of NP
manifestations, malignancies, or severe infections (Non-NPSLE
group), matched by age (65 years) and gender to the NPSLE
patients were studied. They were also evaluated by the study
rheumatologists at hospitalization and six months later identical to
the NPSLE patients. A serum sample was obtained in all the
patients at hospitalization and in 40 patients six months later.
Reasons for hospitalization were: lupus disease activity 43 (SLE
diagnosis, renal, hematological, neumonitis, serositis, hepatitis,
fever), pulmonary thromboembolism 2, and miscellaneous 4.
A serum samplewasalso obtainedfrom 6 SLE patientswith septic
meningitis (SLE septic meningitis group), 16 SLE patients without
NP manifestations ever who underwent an elective surgery (SLE
surgical group), and 25 patients with neither autoimmune diseases
nor NP manifestations (Non-autoimmune group) who also under-
went elective surgery. A CSF sample was obtained from 5 patients of
the septic meningitis group, 16 of the surgical group, and in 17 of the
non-autoimmune group. Patients in the latter two groups gave
writtenpermissiontodonatetheCSFsampleduringthespinalblock.
In all the cases, serum and CSF samples were obtained during
the clinical assessment upon the arrival of the patients at the
hospital. Serum was collected, and CSF was centrifuged at
12,000 g. Serum and the CSF supernatant were immediately
frozen (,30 minutes) at 286uC until assayed for the presence of
autoantibodies.
Detection of autoantibodies
Anti-dsDNA, anti-cardiolipin, and anti-b2 glycoprotein I anti-
bodies of the IgG isotype were detected by immunoenzymatic assay
(EIA) according to the manufacturer’s recommendations (The
Binding Site, Birmingham, UK). Similarly, anti-ribosomal P
antibodies of the IgG isotype were detected by EIA (Orgentec
Diagnostika, Germany). In all instances serum samples were diluted
1:100 and CSF samples were tested undiluted. Anti-NMDAR
antibodies of the IgG isotype were detected by ELISA as previously
described [17]. Briefly, DWEYS peptide was adsorbed to microtiter
plates in 0.1M NaHCO3 (pH 8.6) overnight at 4uC. Serum was
assayed at 1:50 and 1:100 dilution and developed with an enzyme-
tagged antibody to human IgG. Antinuclear antibodies of the IgG
isotype were detected by indirect immunofluorescence according to
the manufacturer’s recommendations (The Binding Site). Serum
samples were diluted 1:40 and CSF samples were tested undiluted.
Three experts read all samples and results were discussed and
registered by consensus. The sera cut-off values for all evaluated
autoantibodies were set above the percentile 90
th of a separate
control group of 100 healthy individuals (ANA .1:40, anti-dsDNA
,9.6 IU/mL, anti-ribosomal P,10.0 U/mL, anti-cardiolipin
,11.5 UGPL, anti-b2g l y c o p r o t e i nI,2.5 U/mL, anti-NMDAR
19.0 O.D.), and the CSF cut-off values for all evaluated
autoantibodies were set above the 90
th percentile of the 17 patients
with non-autoimmune diseases (anti-dsDNA #9.62 IU/mL, anti-
ribosomal P#9.96 U/mL, anti-cardiolipin #4.5 UGPL, anti-b2
glycoprotein I #2.5 U/mL, anti-NMDAR #40.0 O.D.). All
autoantibodies were detected blinded to the status of the patients.
Ethics
The study was approved by the Institutional Committee of
Biomedical Research and all patients signed an informed consent.
Statistical methods
Categorical variables were compared using chi-squared or
Fisher’s exact test, and continuous variables using Student’s t-test,
Mann-Withney U test, Wilcoxon signed-ranks test, paired t-test, or
one-way ANOVA. It was planned in advance to analyze the
prevalence and the levels of the autoantibodies studied between
the Central NPSLE and each one of the other SLE groups, so
corrections for the number of comparisons were not considered. P
value was set at ,0.05, two-tailed. Analysis was performed using
the SPSS 12.0 computer program.
Results
Population characteristics
At entry, the mean6SD age of the NPSLE central and
peripheral patients was 31.5611.6 and 23.866.1 years, respec-
tively; no difference in age was observed across the patient study
groups (P=0.22). As compared with the NPSLE group, non-
NPSLE and SLE-surgical patients had longer disease duration and
the former group also required immunosuppressants more often.
All SLE groups, except the surgical group, had moderate/severe
disease activity and were taking prednisone at high doses. Other
demographic and clinical characteristics were similar among the
study groups (Table 1).
SLE was considered the cause of the NP events in all the
patients; in 21 (45%) patients, no associated factors for the NP
manifestations were identified, and in 26 (55%) patients,
concurrent, non-exclusion factors, i.e. metabolic abnormalities,
high doses of steroids, arterial hypertension were identified [21].
Non-autoimmune disease patients underwent elective surgery
because of: bone marrow donors (7), hysterectomy (8), Tenchkoff
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hydrocele (1), circumcision (1), and inguinal hernioplasty (1).
Septic meningitis was due to: Streptococcus pneumoniae (2), Lysteria
monocytogenes (1), Cryptococcus neoformans (1), Mycobacterium tuberculosis
(1), and Staphylococcus sp. (1).
Autoantibodies in serum
The prevalence of all the autoantibodies was higher across all
the SLE groups than in patients without autoimmune disease.
Anti-ribosomal P antibodies were detected in most patients with
central and peripheral NPSLE, but also in most patients with
septic meningitis. Moreover a third of patients in the non-NPSLE
and the surgical groups were positive for these antibodies.
Anti-NMDAR antibodies were detected in all the SLE patient
groups, except in those with peripheral NPSLE; although the
prevalence was higher in the central NPSLE, non-NPSLE and
septic meningitis groups than in surgical patients, this difference
was not statistically significant. The prevalence of all the other
antibodies did not show clear differences across the SLE groups,
and the levels of all antibodies did not differ among the SLE
groups (Table 2).
Autoantibodies in serum at baseline and 6 months later
Six-months after the hospitalization, the NP manifestations were
considered clinically quiescent in both NPSLE groups, and disease
activity had decreased significantly in the non-NPSLE patients
(Table 1).
A decrease in the levels of anti-dsDNA, anti-ribosomal P, anti-
cardiolipin, anti-b2 glycoprotein-I, and anti-NMDAR antibodies
was observed at six months in patients with central NPSLE who
tested positive at baseline. This decrease was significant only for
the last two autoantibodies. Among the patients with peripheral
NPSLE who tested positive at baseline, the levels of anti-dsDNA
and anti-ribosomal-P antibodies showed a non-significant de-
crease, while anticardiolipin and anti-b2 glycoprotein-I antibodies
remained unchanged. In non-NPSLE patients who tested positive
at baseline, a significant decrease in the levels of anti-dsDNA and
anti-cardiolipin antibodies was observed; the levels of all the other
autoantibodies remained unchanged (Table 3).
Autoantibodies in CSF
In CSF, anti-nuclear, anti-dsDNA, anti-cardiolipin, and anti-b2
glycoprotein antibodies did not show a distinctive pattern across
the SLE groups. In general, patients with septic meningitis had the
highest prevalence for almost all the antibodies (Table 4).
Anti-ribosomal P antibodies did not demonstrate a characteristic
distribution across the SLE groups either, except in patients with
septic meningitis where a significantly higher prevalence than in
patients with central NPSLE was detected. Although the levels of
anti-ribosomal P antibodies tended to be higher in central NPSLE
patients than among the peripheral NPSLE and the surgical groups,
the highest levels were found in patients with septic meningitis.
Anti-NMDAR antibodies were the sole antibodies showing a
distinctive distribution in SLE. Except in one patient from the SLE
surgical and one from the non-autoimmune group, they were found
mostly in patients from the central NPSLE and septic meningitis
groups, and no patient with peripheral NPSLE tested positive. The
levels of anti-NMDAR antibodies were higher in patients with
central NPSLE than inthe other SLE groups,except inpatients with
septic meningitis inwhom the highest levelswere detected.(Table 4).
Autoantibodies in CSF at baseline and 6 months later
Six months after the onset of the central and peripheral NP
manifestations, the prevalence of most antibodies studied
remained similar to the determination at baseline (Table 5).
Among the patients with central NPSLE who tested positive at
baseline, a decrease in the levels of anti-dsDNA, anti-ribosomal P,
and anti-NMDAR antibodies was observed in 14 out of 17, 9 out
of 10, and 7 out of 9 patients, respectively. A significant decrease in
the levels of anti-dsDNA and anti-ribosomal P antibodies was
observed at six months.
Although the levels of anti-NMDAR antibodies seemed to
remain unchanged, this is due to one patient in whom at six
months, the levels increased 3.6 fold in comparison to baseline.
When this patient is excluded from the analysis, a significant
decrease is also observed (82.3633.0 vs. 46.4626.7, P=0.04).
Among the patients with peripheral NPSLE, a non-significant
decrease in the levels of anti-dsDNA and anti-ribosomal P
antibodies was also detected (Table 5).
Table 1. Demographic and clinical characteristics of the study patients at hospitalization.
Central NPSLE
(n=42)
Peripheral NPSLE
(n=5)
Non-NP SLE
(n=49)
SLE-Surgical
(n=16)
SLE-septic
meningitis (n=6)
Non-autoimmune
(n=25)
Age, years
A 31.5611.6 23.866.1 30.7612.0 37.869.8 29.7610.3 37.5615.3
Male/female 7/35 0/5 4/45 2/14 0/6 6/19
SLE duration, years 3.964.4 1.862.4 8.866.5
B 8.867.2
C 3.263.8 –
SLE criteria, No. 5.462.1 663.2 5.062.4 6.162.0 5.361.5 –
SLEDAI–2K score, at baseline 14.969.4 13.268.7 11.567.9 3.861.5
B 10.666.0 –
SLEDAI–2K score, at 6 months 5.465.8 4.066.9 5.966.6 – – –
SLICC/ACR DI score 0.761.2 0.460.9 0.460.8 0.860.4 0.360.5 –
Prednisone use, % 91 100 92 6.3
B 100 –
Prednisone dose, mg/day 44.7624.3 52613.0 41.7622.5 – 55612.2 –
Immunosuppressants use, % 48 100 71
D 25 17
B –
AExcept where indicated otherwise, values are the mean6SD. SLE=systemic lupus erythematosus; NPSLE=neuropsychiatric SLE; SLEDAI-2K=Systemic Lupus
Erythematosus Disease Activity Index 2000 update; SLICC/ACR DI=Systemic Lupus International Collaborating Clinics/ American College of Rheumatology Damage
Index.
BP,0.001 versus Central NPSLE
CP=0.003 versus Central NPSLE
DP=0.02 versus Central NPSLE
doi:10.1371/journal.pone.0003347.t001
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The detection of autoantibodies in serum or CSF in NPSLE
patients has been studied for decades [23]. Unfortunately, the
association between antibodies and nervous system involvement in
SLE remains inconclusive. Moreover, the mechanisms whereby
serum and CSF antibodies reactive with neural tissue are elicited
remain an enigma [16].
In this study, we found a different behaviour of autoantibodies
in serum and CSF at the onset of NPSLE and six months later,
when clinically NP manifestations seemed to be quiescent.
In serum, anti-ribosomal P and anti-NMDAR antibodies were
detected in most SLE groups, and did not differentiate among
groups. Other antibodies implicated in thrombogenesis also did
not show clear differences across the SLE groups, and the levels of
all antibodies did not differ among them. Six-months after the
Table 2. Prevalence and levels of autoantibodies in serum from NPSLE patients and controls.
Autoantibodies positive, no. (%)
Central
NPSLE (42)
Peripheral
NPSLE (n=5)
Non-NP-SLE
(n=49)
SLE-Surgical
(n=16)
SLE-septic
meningitis (n=6)
Non-autoimmune
(n=25)
Antinuclear 33 (79) 4 (80) 44 (90) 14 (88) 6 (100) 3 (12)
B
Anti-ds DNA 34 (81) 5 (100) 37 (76) 11 (69) 4 (67) 4 (16)
B
Anti-ribosomal P 25 (60) 4 (80) 15 (31)
C 6 (38) 5 (83) 3 (12)
B
Anti-cardiolipin (IgG) 8 (19) 2 (40) 13 (27) 2 (13) 2 (33) 1 (4)
Anti-B2-Glycoprotein I (IgG) 26 (62) 4 (80) 27 (55) 9 (56) 5 (83) 3 (12)
C
Anti-N-Methyl-D-Aspartate receptor
A 11 (32) 0 (0) 13 (27) 2 (17) 2 (40) 2 (8)
D
Autoantibodies levels
E
Anti-ds DNA 369.56658.6 163.96292.5 523.96723.6 184.36530.8 427.86506.4 10.660.66
Anti-ribosomal P 94.96153.3 106.96188.7 96.76117.6 126.36184.4 148.56196.3 16.463.8
Anti-cardiolipin (IgG) 38.4656.2 18.668.4 28.4628.2 17.666.9 12.760.99 24.5
Anti-B2-Glycoprotein I (IgG) 15.3647.5 8.967.6 4.363.5 4.561.9 3.961.8 3.961.5
Anti-N-Methyl-D-Aspartate receptor* 28.80612.41 ---- 39.26610.79 21.4162.44 19.6361.93 25.1660.45
NPSLE=neuropsychiatric systemic lupus erythematosus; Non-NPSLE=lupus patients without current or past NP manifestations; SLE-surgical=lupus patients who
underwent elective surgery; SLE-septic meningitis.
AThe NMDAR antibody was measure in 34 central NP SLE patients, 5 peripheral NP SLE patients, 49 non-NPSLE patients, 12 SLE-surgical patients, 5 SLE septic-meningitis
patients, and 25 non-autoimmune patients.
BP,0.001 versus Central NPSLE
CP=0.006 versus Central NPSLE
DP=0.03 versus Central NPSLE
EOnly patients who scored positive at baseline for the specific antibody were considered,
doi:10.1371/journal.pone.0003347.t002
Table 3. Prevalence and levels of autoantibodies in serum of patients with central and peripheral NPSLE, and non-NPSLE at
baseline and 6 months.
Autoantibodies positive,
No. (%)
Central NPSLE
Baseline
(n=34)
Central NPSLE 6
months
(n=34)
P
(%)
Peripheral
NPSLE Baseline
(n=5)
Peripheral
NPSLE 6
months (n=5)
P
(%)
Non-NP-SLE
baseline
(n=40)
Non-NP-SLE 6
months
(n=40)
P
(%)
Antinuclear 28 (82) 25 (74) 0.38 4 (80) 4 (80) 1.0 40 (100) 31 (77) 0.001
Anti-ds DNA 27 (79) 20 (58) 0.07 5 (100) 3 (60) 0.22 30 (75) 28 (70) 0.62
Anti-ribosomal 21 (61) 16 (47) 0.22 4 (80) 5 (100) 1.0 13 (33) 13 (33) 1.0
Anti-cardiolipin, IgG 5 (15) 5 (15) 1.0 2 (40) 1 (20) 1.0 11 (28) 9 (23) 0.60
Anti-B2-Glycoprotein I, IgG 22 (65) 17 (50) 0.22 4 (80) 5 (100) 1.0 23 (58) 19 (48) 0.36
Anti-N-Methyl-D-Aspartate
Receptor (NMDAR)
A
8 (35) 7 (30) 0.75 0 (0) 2 (40) 0.44 12 (30) 10 (25) 0.62
Autoantibodies levels
B
Anti-ds DNA 238.86519.9 41.6676.7 0.06 163.96292.5 37.9638.7 0.22 533.046722.2 162.16399.5 0.008
Anti-ribosomal 96.06157.8 46.5687.3 0.08 106.96188.7 25.8619.8 1.0 69.3698.7 63.56105.2 0.10
Anti-cardiolipin, IgG 51.3670.4 13.665.5 0.13 18.568.4 18.2611.4 0.65 31.7631.6 12.869.6 0.01
Anti-B2-Glycoprotein I, IgG 17.0651.6 4.664.4 0.03 8.967.6 5.661.5 0.46 5.564.5 4.964.2 0.70
Anti-N-Methyl-D-Aspartate
Receptor (NMDAR)
31.0613.0 24.5613.7 0.02 – – – 39.67611.66 50.23623.5 0.28
AThe NMDAR antibody was measured in 23 central and 5 peripheral NPSLE, and in 40 non-NPSLE patients at baseline and 6 months.
BOnly patients who scored positive at baseline for the specific antibody were considered, Central NPSLE/Peripheral NPSLE/non-NPSLE: anti-dsDNA 27/5/30, anti-
ribosomal P 21/4/13, anticardiolipin IgG 5/2/11, anti-b2-glycoprotein-I 22/4/23, anti-NMDAR 8/0/12.
doi:10.1371/journal.pone.0003347.t003
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remained unmodified and the decrease in the levels of some of
them appears to reflect an overall decline in lupus activity.
In CSF, anti-nuclear, anti-dsDNA, anti-cardiolipin, anti-b2
glycoprotein-I, and anti-ribosomal P antibodies did not show a
distinctive pattern across the SLE groups. In contrast, anti-NMDAR
antibodies were found mostly in patients with central NPSLE and in
patients with septic meningitis, and only in one out of 16, and one
out of 17 patients from the surgical SLE and the non-autoimmune
disease groups, respectively. In addition, the levels of anti-NMDAR
antibodies were significantly higher in patients with central NPSLE
than in the peripheral NPSLE and the surgical SLE groups, but not
in patients with septic meningitis. Most patients with central, but not
peripheral, NPSLE who tested positive for anti-dsDNA, anti-
ribosomal P, and anti-NMDAR antibodies at baseline, had a
decrease in the levels of these antibodies at six months.
Table 4. Prevalence and levels of autoantibodies in cerebrospinal fluid from patients with NPSLE and controls.
Autoantibodies Positive, no. (%)
Central NPSLE
(35)
Peripheral NPSLE
(n=5)
SLE-Surgical
(n=16)
SLE-septic meningitis
(n=5)
Non-autoimmune
(n=17)
Antinuclear 20 (57) 5 (100) 7 (44) 5 (100) 0 (0)
1
Anti-ds DNA 27 (77) 3 (60) 10 (63) 4 (80) 0 (0)
2
Anti-ribosomal P 16 (46) 2 (40) 5 (31) 5 (100)
3 1 (6)
3
Anti-cardiolipin, IgG 4 (11) 0 (0) 2 (13) 3 (60)
4 0 (0)
4
Anti-B2-Glycoprotein I, IgG 0 (0) 0 (0) 9 (56)
5 0( 0 ) 0( 0 )
Anti-N-Methyl-D-Aspartate receptor (NMDAR)
7 14 (41) 0 (0) 1 (8)
6 5 (100)
6 1 (4)
6
Autoantibodies levels
8
Anti-ds DNA 1007.562924.2 237.46390.1 24.3619.6 23.8618.3 —
Anti-ribosomal P 542.761649.3 30.9614.4 148.86196.7 632.16962.9 10.5
Anti-cardiolipin, IgG 10.762.7 — 17.666.9 19.569.8 —
Anti-B2-Glycoprotein I, IgG — — 4.561.9 — —
Anti-N-Methyl-D-Aspartate receptor (NMDAR)
7 80.8627.9 — 40.3 89.7649.8 63.0
NPSLE=neuropsychiatric systemic lupus erythematosus; SLE-surgical=lupus patients who underwent elective surgery; SLE-septic meningitis=lupus patients with
septic meningitis, Non-autoimmune=patients without autoimmune diseases.
1P,0.004 versus all SLE groups
2P,0.007 versus all SLE groups
3P,0.005 versus Central NPSLE and SLE-septic meningitis
4P=0.006 versus SLE-septic meningitis
5P,0.05 versus all the other groups
6P,0.02 versus Central NPSLE
7The NMDAR antibody was measure in 34 SLE-CNS patients, 5 SLE-PNS, 12 SLE-surgical, 5 SLE-septic meningitis, and 25 Non-autoimmune patients.
8Autoantibodies levels represent the mean (6SD) among the patients in whom they were positive. The number of patients in each group for a particular antibody
corresponds to the prevalences displayed in the upper panel.
doi:10.1371/journal.pone.0003347.t004
Table 5. Prevalence and levels of autoantibodies in cerebrospinal fluid of patients with central and peripheral NPSLE at baseline
and 6 months
A
Autoantibodies positive, no. (%)
Central NPSLE
Baseline (n=25)
Central NPSLE 6
months (n=25)
P
(%)
Peripheral NPSLE
Baseline (n=5)
Peripheral NPSLE
6 months ( n=5)
P
(%)
Antinuclear 15 (60) 11 (44) 0.26 5 (100) 4 (80) 1.0
Anti-ds DNA 17 (68) 14 (53) 0.61 3 (60) 2 (40) 1.0
Anti-ribosomal 10 (40) 9 (36) 0.95 2 (40) 2 (40) 1.0
Anti-cardiolipin (IgG) 4 (16) 0 (0) 0.11 0 (0) 0 (0) –
Anti-B2-Glycoprotein I (IgG) 0 (0) 0 (0) – 0 (0) 0 (0) –
Anti-N-Methyl-D-Aspartate Receptor (NMDAR) 9 (39) 5 (22) 0.34 0 (0) 2 (40) 0.44
Autoantibodies levels
B
Anti-ds DNA 463.361815.1 17.2617.3 0.03 237.46390.1 10.863.7 0.10
Anti-ribosomal 851.462061.6 25.1621.6 0.01 30.9614.4 12.563.1 0.17
Anti-cardiolipin (IgG) 10.762.7 4.060.5 0.06 – – –
Anti-N-Methyl-D-Aspartate Receptor (NMDAR) 82.9639.9 76.3693.1 0.26 – – –
AThe baseline evaluation was at the time of hospitalization. The NMDAR antibody was measured in 23 central and 5 peripheral NPSLE patients at baseline and 6 months.
BOnly patients who scored positive at baseline for the specific antibody were considered: Central NPSLE/Peripheral NPSLE anti-dsDNA 17/3, anti-ribosomal P 10/2,
anticardiolipin IgG 4/0, anti-NMDAR 9/0.
doi:10.1371/journal.pone.0003347.t005
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unreliability of assessing neurological involvement in SLE patients
by measuring serum autoantibodies. CSF is employed as an
indirect assessment of what could be occurring in the CNS, since
direct access and collection of brain tissue is rarely justified. The
presence of antibodies in the CSF has a twofold explanation: i) in
situ production in the CNS, which has been related to certain
diseases such as multiple sclerosis [24], and ii) a breach in the
blood-brain barrier (BBB), which would allow antibodies access to
a normally restricted compartment [25]. This may explain the
presence and the high levels of all sorts of autoantibodies found in
SLE patients with septic meningitis, since in this condition there is
a clear disruption of the BBB.
Measurement of antibodies in the CSF revealed anti-NMDAR
antibody as an important potential protagonist that was virtually
unnoticed in serum, and this specificity showed a radically
different behaviour from the other antibodies studied. It was the
only antibody that differentiated patients with central from those
with peripheral NPSLE and from the surgical SLE group.
Moreover, high levels of anti-NMDAR antibody were significantly
associated with central NPSLE.
It is worth noting, however, that in the same SLE patients we
detected the presence of all the antibodies tested, except for anti-
NMDARantibody.Thisimpliesthat thesepatients have had,during
the course of their illness, a breach in their BBB that allows access of
antibodies to the CNS. Although infection, stress, hypertension, or
exposure to nicotine may disrupt the BBB [26–29], it is possible that
in lupus flares, the immunological and inflammatory alterations that
occur might allow serum antibodies into the CSF. Another plausible
explanation would be that thebreachof theBBB could be a sporadic
but recurring phenomenon in SLE patients. Indeed, pathologic
studies of patients with NPSLE who died have shown that true
vasculitis of small vessels, the hallmark of lupus pathology, is
generally missing [30]. There are widely scattered microinfarcts and
a non-inflammatory vasculopathy, characterized by intimal prolif-
eration and perivascular gliosis [31]. This bland vasculopathy does
not generally correlate with the clinical findings, and it may be
present in patients without NP involvement. Thus, antibodies may
gain entry into the CNS through an alteration of the BBB, perhaps
resulting from damage visualised as bland vasculopathy.
When clinically NP manifestations had been resolved, we did not
observe a decrease in CSF in the prevalence of the autoantibodies
tested in patients with central and peripheral NPSLE. Nevertheless,
among the patients with central NPSLE who tested positive at
baseline, a decrease in the levels of anti-dsDNA, anti-ribosomal P,
and anti-NMDAR antibodies was observed. This observation may
suggest that their presence could be conditioning a sort of damage
that we were unable to detect clinically or radiologically.
Recently, wereported theparticipationofIL-6 and chemokinesin
these patients and showed that the levels of practically all the
molecules that had originally shown high concentrations decreased
significantly, although not as far as the levels found in the patients
without autoimmune diseases [32]. Rather, they reached a range of
values that could bedefined asthe basal level inSLE,since they were
similar to the levels found in the non-NPSLE patients. The same
seems to occur with autoantibodies. This is of the highest
importance, because SLE patients show long term neurological
damage, which manifests itself as a decrease in brain volume and a
worsening of cognitive function [33,34]. Although this worsening is
greater in patients with history of NPSLE, it is also observed in
patients without previous NP manifestations [35]. One must
emphasize that the anti-NMDAR antibody has been categorized
as a mediator for cognitive impairment [17]. There is no recognized
aetiology of these alterations; it is possible, however, that this slight,
but persistent increase in chemokines and antibodies levels in the
CSF of SLE patients elicits this damage by maintaining a chronic
subclinical inflammation or progressive neuronal loss.
Limitations
In order to define the borders of our results, we must highlight
some potential limitations. 1) Although a relatively large number of
patients with NP manifestations were included and we did detect a
correlation between CNS disease and specific antibodies, we were
unable to correlate specific antibodies with specific manifestations,
since thestudywas notadequately poweredforthem.Therefore, our
results should be interpreted with caution since NPSLE manifesta-
tions are likely to be due to heterogeneous mechanisms [36]. 2)
Furthermore, a limited number of patients with peripheral NP
manifestations were included, which could raise concerns about the
generalization of our results. The pathogenic mechanism of these
manifestations, however, is likely to be different from that of central
manifestations, and we therefore consider that the results obtained,
illustrate the behaviour of the antibodies studied in the central and
peripheral NP manifestations. 3) We included patients with NP
manifestations attributable to SLE according to the ACR nomen-
clature, rejecting patients with exclusion factors for the attribution of
the NPmanifestations [20],and patients with minorevents that have
a comparable frequency in the normal population [21]. Neverthe-
less, in 48 percent of our patients, there were concurrent non-SLE
factors, which might have contributed to the development of
symptoms. Since this is a complex issue, some misclassification in the
attribution may be present. 4) Our results apply to patients with
acute NP manifestations who needed to be hospitalized for their
diagnosis and/or treatment. We did not study non-hospitalized
patients, or patients with chronic serious manifestations, e.g.
depression, seizures or cognitive dysfunction. 5) We did not carry
out an in-depth screening for NP manifestations among the patients
withouthistoryforthem,thereforealthoughnoneofthemhadanyof
the acute and severe manifestations included among the patients
with central and peripheral NPSLE, we cannot exclude that they
had mild or subclinical NP manifestations. 6) Although at six
months, the NPSLE patients were clinically in remission, we cannot
exclude ongoing, subclinical NP activity which might associate with
the presence and levels of the antibodies studied in CSF.
Ourstudy also hasstrengthsthatneed to beemphasized. 1) Thisis
the first study to assess the levels of several antibodies simultaneously
in serum and in CSF, in various groups of patients with SLE and in
subjects without autoimmune disease. Thus, several groups of
negative controls were assembled as well as SLE patients with
infectious meningitis in whom an inflammatory global process in the
meninges,notduetolupusactivity,waspresent.Thispositivecontrol
group allows us to determine the specificity of the antibodies studied
as markers of NP activity due to lupus. 2) The paired assessment in
serum and CSF of autoantibodies during the acute episode and six
months later provides unique information about the sensitivity of the
levels of autoantibodies to change in the status of NP manifestations.
3) All patients were assessed prospectively following a standardized
evaluation, and the antibody determination was blinded to the
diagnosis and the study group. Furthermore, all patient sera and
CSF was evaluated simultaneously to avoid intra-assay variabililty.
Overall, our results provide answers and more questions in the
complex challenge that represents CNS involvement in SLE.
1. We clearly show a lack of correlation of serum antibodies to
NPSLE manifestations.
2. We also demonstrate that when studying the pathogenesis of
NPSLE, it will be important to subdivide CNS and PNS
manifestations.
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of antibodies in acute manifestations of NPSLE.
Several questions remain, which should be answered with future
research:
i) Do anti-ribosomal P and anti-NMDAR antibodies contribute
to CNS damage in patients with SLE and infectious
meningitis, with the clinical manifestations of meningitis
masking the symptoms of NPSLE?
ii) Do the selective expression of NMDARs in the CNS account
for the exquisite tropism towards CNS on the part of anti-
NMDAR antibody and not of the other antibodies studied?
iii) Why does the anti-NMDAR antibody persist in CSF for such
a long time at a high level? Alternatively, why does this
antibody cross the BBB persistently and in a selective manner
in central NPSLE patients? Does the continued presence of
this antibody explain the insidious nature of the cognitive
impairment observed in SLE patients?
In conclusion, our results do not support the quantification in
serum of the autoantibodies tested as a diagnostic tool; however,
we believe that they play an important role in the pathogenesis of
NPSLE, particularly the anti-NMDAR antibody in central
nervous system involvement. The concomitant measurement of
other potentially involved molecules such as cytokines is needed to
delineate the molecular basis for each NP manifestation, focusing
on CSF samples. The damage to the BBB both in NPSLE and
non-NPSLE patients has been underestimated [17,25]. It is
therefore essential to aim our efforts at trying to ascertain the
mechanisms responsible for altering the BBB integrity, and to
reduce the process leading to the CNS involvement in SLE.
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